ML385: Selective NRF2 Inhibitor for Cancer & Redox Research

Executive Summary: ML385 (CAS 846557-71-9) is a small molecule NRF2 inhibitor with an IC50 of 1.9 μM and high selectivity for NRF2 signaling pathway inhibition (APExBIO product information). It efficiently downregulates NRF2-dependent genes in NSCLC (A549) cells and reduces tumor progression in mouse models, especially when combined with chemotherapy. ML385 is instrumental in research investigating oxidative stress, ferroptosis, and mechanisms of cancer therapeutic resistance (Zhou et al., 2024). Its solubility profile (insoluble in water, soluble in DMSO at ≥13.33 mg/mL) and recommended storage conditions (-20°C) are critical for reproducibility.

Biological Rationale

Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor central to cellular antioxidant defense and detoxification. It regulates genes involved in redox homeostasis, NADPH metabolism, and multidrug resistance (Zhou et al., 2024). Aberrant NRF2 activation contributes to cancer progression and resistance mechanisms, notably in non-small cell lung cancer (NSCLC). Recent studies also implicate NRF2 in ferroptosis, an iron-dependent form of cell death relevant to liver and cancer pathologies. Inhibiting NRF2 provides researchers with a means to dissect these pathways under pathological stress and chemotherapeutic challenge (see detailed dossier—this article details direct in vitro and in vivo validation, contrasting prior reviews).

Mechanism of Action of ML385

ML385 binds selectively to the NRF2 transcription factor, inhibiting its DNA binding activity and downstream transcriptional activation. This results in dose- and time-dependent downregulation of NRF2 target genes, including those coding for antioxidant enzymes and multidrug resistance proteins (APExBIO). In A549 NSCLC cells, ML385 treatment leads to significant reductions in NRF2-dependent gene expression, with maximal inhibition observed at 1.9 μM. The molecule is chemically defined as 2-(benzo[d][1,3]dioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)indolin-5-yl)thiazol-2-yl)acetamide (MW 511.59, formula C29H25N3O4S).

Evidence & Benchmarks

• ML385 exhibits an IC50 of 1.9 μM for NRF2 inhibition in A549 NSCLC cell lines (APExBIO).
• In vivo, ML385 reduces tumor growth and metastasis in NSCLC mouse models, with enhanced efficacy in combination with carboplatin (APExBIO).
• ML385 abrogates NRF2 signaling and downstream antioxidant gene expression in both cancer and alcoholic liver disease models, facilitating oxidative damage and ferroptosis (Zhou et al., 2024).
• ML385 is insoluble in water and ethanol, but soluble at ≥13.33 mg/mL in DMSO; storage at -20°C as solid or frozen solution is advised (APExBIO).
• Application of ML385 at 100 mg/kg/day intraperitoneally in rat models successfully inhibited NRF2, enabling mechanistic dissection of oxidative stress and ferroptosis in vivo (Zhou et al., 2024).

For a broader translational context, see the strategic guidance in Decoding NRF2 Inhibition with ML385, which expands on preclinical workflows beyond NSCLC and liver models.

Applications, Limits & Misconceptions

ML385 is primarily used in preclinical research to interrogate NRF2 pathway function in cancer, liver disease, ferroptosis, and redox stress. Its selective inhibition allows for precise modulation of NRF2-dependent transcriptional responses. However, its use is confined to research settings; it is not approved for diagnostic or therapeutic applications (APExBIO).

Common Pitfalls or Misconceptions

• ML385 is not water-soluble; improper solvent use can compromise activity and reproducibility.
• It is not suitable for clinical or diagnostic applications; intended for in vitro and animal model research only.
• NRF2 inhibition by ML385 may be context-dependent; off-target effects have not been exhaustively ruled out in cell types outside NSCLC and liver models.
• Long-term storage of ML385 solutions is not recommended due to stability concerns; prepare aliquots as needed.
• ML385 does not block all antioxidant pathways—its specificity is for NRF2-mediated gene expression only.

This article extends the guidance in ML385: Selective NRF2 Inhibitor for Cancer Research Workflows by directly addressing solubility, stability, and validated in vivo dosing strategies.

Workflow Integration & Parameters

• Solubility: Dissolve ML385 in DMSO at concentrations ≥13.33 mg/mL; avoid water and ethanol (APExBIO).
• Storage: Store as a solid or frozen DMSO solution at -20°C. Do not store diluted solutions long-term.
• In vitro application: Typical working concentrations range from 0.5–10 μM, with maximal NRF2 inhibition at 1.9 μM in A549 cells.
• In vivo protocol: For rodent studies, intraperitoneal injection of 100 mg/kg/day has been validated for NRF2 pathway inhibition in liver disease models (Zhou et al., 2024).
• Combination therapy: ML385 can be co-administered with chemotherapeutics such as carboplatin to enhance anti-tumor effects.

For troubleshooting and advanced protocol tips, the article ML385: Advancing Redox and Cancer Research provides additional insights, particularly on experimental design and redox endpoints—this complements the present article's focus on quantitative benchmarks.

Conclusion & Outlook

ML385 is a rigorously validated, highly selective NRF2 inhibitor for cancer and redox biology research. Its reproducible efficacy in NSCLC and liver disease models makes it a standard tool for dissecting NRF2-dependent pathways and therapeutic resistance (Zhou et al., 2024). Further refinement of dosing protocols and expanded benchmarking in new disease contexts remain active areas of research. The evidence base supports ML385 as a central reagent for mechanistic studies but underscores its restriction to non-clinical, preclinical research domains.